行情

TARA

TARA

ArTara Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

28.00
+0.18
+0.65%
休市 16:00 01/17 EST
开盘
28.02
昨收
27.82
最高
28.30
最低
27.03
成交量
2,474
成交额
--
52周最高
157.60
52周最低
8.80
市值
8,206.23万
市盈率(TTM)
-0.0182
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TARA 新闻

  • 外盘头条:一百多名亿万富翁即将齐聚达沃斯
  • 新浪美股.1小时前
  • LVMH股价去年大涨60% 实控人成最新福布斯富豪榜榜首
  • 新浪财经综合.3小时前
  • 英国央行行长称:全球经济正陷入“流动性陷阱”
  • 新浪美股.3小时前
  • 弹劾案审讯开始在即 民主党人、特朗普律师提交主张
  • 新浪财经.3小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

TARA 简况

ArTara Therapeutics Inc., formerly Proteon Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. Its product pipeline includes TARA 002 and IV choline chloride for injection. TARA 002 is its lead program focused on the treatment of Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an enzyme replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD).
展开

Webull提供Artara Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。